Fulcrum Therapeutics
OverviewSuggest Edit
The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation.
The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating – or balancing – the expression of the genes known to drive disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
| Type | Public | |
| Founded | 2016 | |
| HQ | Cambridge, US | Map |
| Website | fulcrumtx.com |
Recent NewsAll News
- Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
- Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
- Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference
- Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET
Key People/Management at Fulcrum Therapeutics
Robert J. Gould
President and Chief Executive Officer, Board Member
Owen Wallace
Chief Scientific Officer
Pamela S. Strode
Senior Vice President, Regulatory Affairs and Quality Assurance
Diego Cadavid
Senior Vice President, Clinical Development
Christopher Moxham
Senior Vice President, Discovery
Lucienne Ronco
Vice President, Translational Medicine
Fulcrum Therapeutics Office Locations
Fulcrum Therapeutics has an office in Cambridge
Cambridge, US (HQ)
26 Landsdowne St
Fulcrum Therapeutics Financials and Metrics
Fulcrum Therapeutics Revenue
| USD | |
|---|---|
Revenue (Q2, 2020) | 2.0m |
Net income (Q2, 2020) | (15.7m) |
EBIT (Q2, 2020) | (15.9m) |
Market capitalization (16-Oct-2020) | 300.1m |
Closing stock price (16-Oct-2020) | 10.9 |
Cash (30-Jun-2020) | 75.7m |
Fulcrum Therapeutics's current market capitalization is $300.1 m.
Annual
Annual
| USD | FY, 2017 |
|---|---|
Financial Leverage | 3.3 x |
Fulcrum Therapeutics Cybersecurity Score
Fulcrum Therapeutics Online and Social Media Presence
501 Twitter followers
Fulcrum Therapeutics has 501 Twitter Followers. The number of followers has increased 0.9% month over month and increased 2.7% quarter over quarter
Fulcrum Therapeutics's Trends
Twitter Engagement Stats for @FulcrumTx
691
Tweets
154
Following
501
Followers
14
Tweets last 30 days
2.4
Avg. likes per Tweet
78.6%
Tweets with engagement
Fulcrum Therapeutics News and Updates
October 05, 2020
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Investigational New Drug application (IND) is now i…
October 01, 2020
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the company’s ongoing stu…
August 11, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
– Conference call scheduled for 8:00 a.m. ET today –
June 10, 2020
Fulcrum Therapeutics Completes $68.5 Million Private Placement
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced the closing of a $68.5 million private placement pursuant to a securities purchase agreement with a group of institutional investors and accredited investors.
March 05, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results
Conference call scheduled for 8:00 a.m. ET today Conference call scheduled for 8:00 a.m. ET today
February 25, 2020
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Thursday, March 5, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2019 financial results …
Fulcrum Therapeutics Blogs
May 21, 2020
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
Content Import
Thu, 05/21/2020 - 07:00
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Hig…
May 13, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
Conference call scheduled for 8:00 a.m. ET today CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC) , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business
May 11, 2020
Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the
May 07, 2020
Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2020 financial results will be released
April 13, 2020
Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease
CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it is on track for submission of an Investigational New Drug
April 02, 2020
Fulcrum Therapeutics Provides Business Update on Impact of COVID-19
CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update in the context of the developing situation
Fulcrum Therapeutics Frequently Asked Questions
When was Fulcrum Therapeutics founded?
Fulcrum Therapeutics was founded in 2016.
Who are Fulcrum Therapeutics key executives?
Fulcrum Therapeutics's key executives are Robert J. Gould, Owen Wallace and Pamela S. Strode.
How many employees does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 73 employees.
Who are Fulcrum Therapeutics competitors?
Competitors of Fulcrum Therapeutics include Metacrine, Yumanity Therapeutics and PamBio.
Where is Fulcrum Therapeutics headquarters?
Fulcrum Therapeutics headquarters is located at 26 Landsdowne St, Cambridge.
Where are Fulcrum Therapeutics offices?
Fulcrum Therapeutics has an office in Cambridge.
How many offices does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies